Interferon-gamma-producing CD4+ T-cell (Th1 cell)

Interferon-gamma-producing CD4+ T-cells, commonly known as T helper type 1 (Th1) cells, are a specialized lineage of effector T lymphocytes central to the adaptive immune system [7, 13]. These cells differentiate from naive CD4+ T-cells under the influence of interleukin-12 (IL-12) and are defined by the expression of the master transcription factor T-bet and the secretion of the pro-inflammatory cytokine interferon-gamma (IFN-gamma) [6, 9]. Their primary biological function is to orchestrate cell-mediated immunity against intracellular pathogens, such as Mycobacterium tuberculosis and various viruses, by activating macrophages and enhancing their microbicidal capabilities [2, 7].\n\nIn clinical medicine, Th1 cells are a major focus due to their role in the pathogenesis of numerous autoimmune and chronic inflammatory diseases where their over-activation leads to tissue damage, as seen in Crohn's disease, rheumatoid arthritis, and psoriasis [1, 3, 5]. Conversely, they are vital for effective antitumor responses, where they promote a cytotoxic microenvironment and support CD8+ T-cell activity [9, 15]. Therapeutic interventions targeting this population often involve monoclonal antibodies that block the IL-12/Th1 axis to alleviate inflammation or agents that modulate the IFN-gamma signaling pathway [1, 6, 9].

Other names

T helper type 1 cellTh1 lymphocyteType 1 T helper cellIFN-gamma+ CD4+ T-cellIFNγ+ CD4+ T-cell

Drugs targeting this cell population primarily act by inhibiting differentiation (e.g., IL-12 blockade), neutralizing effector cytokines (e.g., IFN-gamma or TNF-alpha antagonism), or suppressing intracellular signaling pathways (e.g., JAK-STAT inhibition) required for cellular activation and survival.